ATE324106T1 - Zusammensetzungen und verfahren zur regulierung des serumcholesterins - Google Patents

Zusammensetzungen und verfahren zur regulierung des serumcholesterins

Info

Publication number: ATE324106T1
Authority: AT; Austria
Prior art keywords: serum cholesterol; identified; methods; drugs; compositions
Prior art date: 1999-02-24

Application number

AT00910316T

Other languages

English (en)

Inventor

Subroto Chatterjee

Original Assignee

Univ Johns Hopkins

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-24

Filing date

2000-02-23

Publication date

2006-05-15

2000-02-23 Application filed by Univ Johns Hopkins filed Critical Univ Johns Hopkins

2006-05-15 Application granted granted Critical

2006-05-15 Publication of ATE324106T1 publication Critical patent/ATE324106T1/de

Links

HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 5
238000000034 method Methods 0.000 title abstract 3
239000000203 mixture Substances 0.000 title abstract 2
230000001105 regulatory effect Effects 0.000 title 1
229940113549 Cholesterol inhibitor Drugs 0.000 abstract 2
241000124008 Mammalia Species 0.000 abstract 2
239000003524 antilipemic agent Substances 0.000 abstract 2
239000003814 drug Substances 0.000 abstract 2
229940079593 drug Drugs 0.000 abstract 2
102000000853 LDL receptors Human genes 0.000 abstract 1
108010001831 LDL receptors Proteins 0.000 abstract 1
108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 abstract 1
102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
239000012636 effector Substances 0.000 abstract 1
230000035800 maturation Effects 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1
150000003408 sphingolipids Chemical class 0.000 abstract 1
230000000087 stabilizing effect Effects 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04003—Phospholipase C (3.1.4.3)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/22—Cysteine endopeptidases (3.4.22)
- C12Y304/22056—Caspase-3 (3.4.22.56)
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Obesity (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Endocrinology (AREA)
Food Science & Technology (AREA)
Transplantation (AREA)
Oncology (AREA)
Virology (AREA)
Child & Adolescent Psychology (AREA)
Biophysics (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)

AT00910316T 1999-02-24 2000-02-23 Zusammensetzungen und verfahren zur regulierung des serumcholesterins ATE324106T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US12144799P	1999-02-24	1999-02-24

Publications (1)

Publication Number	Publication Date
ATE324106T1 true ATE324106T1 (de)	2006-05-15

Family

ID=22396797

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00910316T ATE324106T1 (de)	1999-02-24	2000-02-23	Zusammensetzungen und verfahren zur regulierung des serumcholesterins

Country Status (8)

Country	Link
EP (1)	EP1155121B1 (de)
JP (1)	JP2002537407A (de)
AT (1)	ATE324106T1 (de)
AU (1)	AU776785B2 (de)
CA (1)	CA2362549A1 (de)
DE (1)	DE60027551T2 (de)
ES (1)	ES2261187T3 (de)
WO (1)	WO2000050574A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2003043624A1 (en)	2001-11-16	2003-05-30	Bristol-Myers Squibb Company	Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
ES2325260T3 (es)	2003-01-20	2009-08-31	Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno	Utilizacion de esfingolipidos para reducir los niveles de triacilglicerol y colesterol en el plasma.
NL1022443C2 (nl)	2003-01-20	2004-07-22	Tno	Sphingolipiden voor verbetering van de samenstelling van de darmflora.
US7371759B2 (en)	2003-09-25	2008-05-13	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
US7420059B2 (en)	2003-11-20	2008-09-02	Bristol-Myers Squibb Company	HMG-CoA reductase inhibitors and method
ATE500752T1 (de) *	2004-03-16	2011-03-15	Tno	Verwendung von sphingolipiden bei der behandlung und vorbeugung von typ-2-diabetes mellitus, insulinresistenz und metabolismussyndrom
US7572805B2 (en)	2004-07-14	2009-08-11	Bristol-Myers Squibb Company	Pyrrolo(oxo)isoquinolines as 5HT ligands
EP1618876A1 (de) *	2004-07-19	2006-01-25	Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO	Verwendung von Sphingolipiden zur Vorbeugung und Behandlung von Atherosklerose
US7517991B2 (en)	2004-10-12	2009-04-14	Bristol-Myers Squibb Company	N-sulfonylpiperidine cannabinoid receptor 1 antagonists
EP1661562A1 (de) *	2004-11-30	2006-05-31	Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO	Verwendung von Sphingolipiden zur Behandlung und Vorbeugung von Steatose
US7906488B2 (en)	2004-11-30	2011-03-15	Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno	Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae
WO2006076598A2 (en)	2005-01-12	2006-07-20	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid receptor modulators
US7368458B2 (en)	2005-01-12	2008-05-06	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076569A2 (en)	2005-01-12	2006-07-20	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid receptor modulators
US20060160850A1 (en)	2005-01-18	2006-07-20	Chongqing Sun	Bicyclic heterocycles as cannabinoid receptor modulators
EP1846410B1 (de)	2005-02-10	2009-01-21	Bristol-Myers Squibb Company	Dihydrochinazolinone als 5ht-modulatoren
US7452892B2 (en)	2005-06-17	2008-11-18	Bristol-Myers Squibb Company	Triazolopyrimidine cannabinoid receptor 1 antagonists
TW200726765A (en)	2005-06-17	2007-07-16	Bristol Myers Squibb Co	Triazolopyridine cannabinoid receptor 1 antagonists
US7629342B2 (en)	2005-06-17	2009-12-08	Bristol-Myers Squibb Company	Azabicyclic heterocycles as cannabinoid receptor modulators
US7632837B2 (en)	2005-06-17	2009-12-15	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid-1 receptor modulators
AU2006264407B2 (en) *	2005-07-04	2012-08-30	Ramu Krishnan	Improved drug or pharmaceutical compounds and a preparation thereof
US7795436B2 (en)	2005-08-24	2010-09-14	Bristol-Myers Squibb Company	Substituted tricyclic heterocycles as serotonin receptor agonists and antagonists
US8618115B2 (en)	2005-10-26	2013-12-31	Bristol-Myers Squibb Company	Substituted thieno[3,2-d]pyrimidinones as MCHR1 antagonists and methods for using them
US7553836B2 (en)	2006-02-06	2009-06-30	Bristol-Myers Squibb Company	Melanin concentrating hormone receptor-1 antagonists
EP1923060A1 (de) *	2006-11-08	2008-05-21	Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO	Zusammensetzungen von einem Sphingolipiden und einem HMG-CoA-Reduktase-Hemmer zur Behandlung von Hypercholesterämie
US20090011994A1 (en)	2007-07-06	2009-01-08	Bristol-Myers Squibb Company	Non-basic melanin concentrating hormone receptor-1 antagonists and methods
DE102007051338A1 (de) *	2007-10-26	2009-04-30	Müller-Enoch, Dieter, Prof. Dr.	Verwendung von substituierten Glycerinderivaten zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung und zur Vorbeugung von Dyslipidämien
PE20091928A1 (es)	2008-05-29	2009-12-31	Bristol Myers Squibb Co	Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
SG174504A1 (en)	2009-03-27	2011-10-28	Bristol Myers Squibb Co	Methods for preventing major adverse cardiovascular events with dpp-iv inhibitors
EP2892897A1 (de)	2012-09-05	2015-07-15	Bristol-Myers Squibb Company	Pyrrolon- oder pyrrolidinon-antagonisten des melaninkonzentrierenden hormonrezeptor-1
EP2892896B1 (de)	2012-09-05	2016-06-29	Bristol-Myers Squibb Company	Pyrrolon- oder pyrrolidinon-antagonisten des melaninkonzentrierenden hormonrezeptor-1
WO2020016335A1 (en)	2018-07-19	2020-01-23	Astrazeneca Ab	Methods of treating hfpef employing dapagliflozin and compositions comprising the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3876789A (en) *	1972-03-31	1975-04-08	American Home Prod	(2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides, as anti-lipemic agents
US5498696A (en) *	1993-05-13	1996-03-12	Board Of Regents, The University Of Texas System	Sterol regulatory element binding proteins and their use in screening assays
FR2747307B1 (fr) *	1996-04-11	1998-07-10	Ravi Shrivastava	Application a titre de medicament des ceramides et compositions notamment pharmaceutiques les renfermant

2000
- 2000-02-23 EP EP00910316A patent/EP1155121B1/de not_active Expired - Lifetime
- 2000-02-23 AT AT00910316T patent/ATE324106T1/de not_active IP Right Cessation
- 2000-02-23 ES ES00910316T patent/ES2261187T3/es not_active Expired - Lifetime
- 2000-02-23 AU AU32429/00A patent/AU776785B2/en not_active Ceased
- 2000-02-23 CA CA002362549A patent/CA2362549A1/en not_active Abandoned
- 2000-02-23 DE DE60027551T patent/DE60027551T2/de not_active Expired - Fee Related
- 2000-02-23 WO PCT/US2000/004657 patent/WO2000050574A1/en not_active Ceased
- 2000-02-23 JP JP2000601138A patent/JP2002537407A/ja active Pending

Also Published As

Publication number	Publication date
DE60027551T2 (de)	2007-05-10
EP1155121B1 (de)	2006-04-26
EP1155121A1 (de)	2001-11-21
EP1155121A4 (de)	2003-09-17
CA2362549A1 (en)	2000-08-31
DE60027551D1 (de)	2006-06-01
ES2261187T3 (es)	2006-11-16
AU3242900A (en)	2000-09-14
JP2002537407A (ja)	2002-11-05
AU776785B2 (en)	2004-09-23
WO2000050574A1 (en)	2000-08-31

Legal Events

Date	Code	Title	Description
2006-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE60027551D1 (de)	2006-06-01	Zusammensetzungen und verfahren zur regulierung des serumcholesterins
ATE364696T1 (de)	2007-07-15	Abc1 polypeptide und verfahren und reagenzien zur modulation des cholesterolgehalts
ATE427499T1 (de)	2009-04-15	Zusammensetzungen und verfahren zur quantifizierung von serumglykoproteinen
ECSP045520A (es)	2005-03-10	Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
ATE361067T1 (de)	2007-05-15	Naphtoquinone derivate als inhibitoren von tau aggregation zur behandlung von alzheimer's und verbundenen neurodegenerativen erkrankungen
DE69625691D1 (de)	2003-02-13	Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
EP1402067A4 (de)	2005-04-27	Hs2sts als modifikatoren des p53-wegs und verwendungsverfahren
DE69805973D1 (de)	2002-07-18	Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69936948D1 (de)	2007-10-04	Virusenthaltende Zusammensetzungen und Methoden zur Konzentration von Viruspräparaten
BR0317896A (pt)	2005-12-06	Complexos de cristais de proteìna e polìmeros iÈnicos
ATE225351T1 (de)	2002-10-15	Thienopyridin und thienopyrimidinderivate und ihre verwendung als entzündungshemmende mittel
ATE448775T1 (de)	2009-12-15	Rifalazil zur behandlung von infektionen mit clostridium difficile
SE8902532D0 (sv)	1989-07-14	Bestaemning av plasmaproteiner
DE69932845D1 (de)	2006-09-28	Methoden zur quantifizierung von hla-dr und cd11b
DE60323592D1 (de)	2008-10-30	Verfahren zur Identifizierung von Agenzien zur Behandlung von Anfällen, neurologischen Erkrankungen, Endokrinopathien und hormonalen Erkrankungen
ATE319439T1 (de)	2006-03-15	Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
ATE279386T1 (de)	2004-10-15	Retinoide zur behandlung von emphysem
EP1109548A4 (de)	2001-12-12	Zusammensetzungen und verfahren zur behandlung und vorbeugung von knochenkrankheiten unter verwendung von tocotrienole
DE69927147D1 (de)	2005-10-13	Verwendung von osteoprotegerin zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE69840752D1 (de)	2009-05-28	Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
DE60035693D1 (de)	2007-09-06	Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten
DE69918972D1 (de)	2004-09-02	Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE69908644D1 (de)	2003-07-10	Kombnationen von cholesteryl ester transfer protein inhibitoren und gallensäure sequestriermitteln für kardiovaskuläre indikationen
DE69433243D1 (de)	2003-11-20	Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
DE69838667D1 (de)	2007-12-20	Verfahren zur stabilisierung nützlicher proteine und nützliche proteinhaltige mittel